All 0 3 0 3 B-gender
women 4 9 4 9 I-gender
of 10 12 10 12 O
childbearing 13 25 13 25 O
potential 26 35 26 35 O
must 36 40 36 40 O
have 41 45 41 45 O
a 46 47 46 47 O
negative 48 56 48 56 B-pregnancy
serum 57 62 57 62 I-pregnancy
pregnancy 63 72 63 72 I-pregnancy
test 73 77 73 77 O
and 78 81 78 81 O
male 82 86 82 86 B-gender
and 87 90 87 90 I-gender
female 91 97 91 97 I-gender
subjects 98 106 98 106 I-gender
must 107 111 107 111 O
agree 112 117 112 117 B-contraception_consent
to 118 120 118 120 I-contraception_consent
use 121 124 121 124 I-contraception_consent
effective 125 134 125 134 I-contraception_consent
means 135 140 135 140 I-contraception_consent
of 141 143 141 143 I-contraception_consent
contraception 144 157 144 157 I-contraception_consent
( 158 159 158 159 O
surgical 159 167 159 167 B-contraception_consent
sterilization 168 181 168 181 I-contraception_consent
or 182 184 182 184 O
the 185 188 185 188 O
use 189 192 189 192 O
or 193 195 193 195 O
barrier 196 203 196 203 B-contraception_consent
contraception 204 217 204 217 I-contraception_consent
with 218 222 218 222 O
either 223 229 223 229 O
a 230 231 230 231 O
condom 232 238 232 238 B-contraception_consent
or 239 241 239 241 O
diaphragm 242 251 242 251 B-contraception_consent
in 252 254 252 254 I-contraception_consent
conjunction 255 266 255 266 I-contraception_consent
with 267 271 267 271 I-contraception_consent
spermicidal 272 283 272 283 I-contraception_consent
gel 284 287 284 287 I-contraception_consent
or 288 290 288 290 O
an 291 293 291 293 O
IUD 294 297 294 297 B-contraception_consent
) 297 298 297 298 O
with 299 303 299 303 O
their 304 309 304 309 O
partner 310 317 310 317 O
from 318 322 318 322 O
entry 323 328 323 328 O
into 329 333 329 333 O
the 334 337 334 337 O
study 338 343 338 343 O
through 344 351 344 351 O
6 352 353 352 353 B-upper_bound
months 354 360 354 360 I-upper_bound
after 361 366 361 366 I-upper_bound
the 367 370 367 370 O
last 371 375 371 375 O
dose 376 380 376 380 O

At 0 2 381 383 O
least 3 8 384 389 O
18 9 11 390 392 B-lower_bound
years 12 17 393 398 I-lower_bound
of 18 20 399 401 O
age 21 24 402 405 B-age

ECOG 0 4 406 410 B-clinical_variable
performance 5 16 411 422 I-clinical_variable
status 17 23 423 429 I-clinical_variable
of 24 26 430 432 O
0 27 28 433 434 B-lower_bound
to 29 31 435 437 O
2 32 33 438 439 B-upper_bound

For 0 3 440 443 O
cohorts 4 11 444 451 O
1 12 13 452 453 B-lower_bound
- 13 14 453 454 O
3 14 15 454 455 B-upper_bound
, 15 16 455 456 O
tumor 17 22 457 462 B-cancer
volumes 23 30 463 470 O
limited 31 38 471 478 O
to 39 41 479 481 O
1.5cc 42 47 482 487 O
, 47 48 487 488 O
as 49 51 489 491 O
calculated 52 62 492 502 O
under 63 68 503 508 O
4.1 69 72 509 512 O
Inclusion 73 82 513 522 O
criteria 83 91 523 531 O

Gastrointestinal 0 16 532 548 B-chronic_disease
perforation 17 28 549 560 I-chronic_disease
, 28 29 560 561 O
abdominal 30 39 562 571 B-chronic_disease
fistula 40 47 572 579 I-chronic_disease
, 47 48 579 580 O
intra- 49 55 581 587 B-chronic_disease
abdominal 56 65 588 597 I-chronic_disease
abscess 66 73 598 605 I-chronic_disease
within 74 80 606 612 O
1 81 82 613 614 B-upper_bound
year 83 87 615 619 I-upper_bound

Histologically 0 14 620 634 O
confirmed 15 24 635 644 O
glioblastoma 25 37 645 657 B-cancer

History 0 7 658 665 O
or 8 10 666 668 O
clinical 11 19 669 677 O
evidence 20 28 678 686 O
of 29 31 687 689 O
pancreatitis 32 44 690 702 B-chronic_disease
within 45 51 703 709 O
2 52 53 710 711 B-upper_bound
years 54 59 712 717 I-upper_bound

Life 0 4 718 722 B-clinical_variable
expectancy 5 15 723 733 I-clinical_variable
of 16 18 734 736 O
at 19 21 737 739 O
least 22 27 740 745 O
2 28 29 746 747 B-lower_bound
months 30 36 748 754 I-lower_bound

Myocardial 0 10 755 765 B-chronic_disease
infarction 11 21 766 776 I-chronic_disease
, 21 22 776 777 O
stroke 23 29 778 784 B-chronic_disease
, 29 30 784 785 O
transient 31 40 786 795 B-chronic_disease
ischemic 41 49 796 804 I-chronic_disease
attack 50 56 805 811 I-chronic_disease
within 57 63 812 818 O
6 64 65 819 820 B-upper_bound
months 66 72 821 827 I-upper_bound

Planned 0 7 828 835 O
stereotactic 8 20 836 848 B-treatment
biopsy 21 27 849 855 I-treatment
as 28 30 856 858 O
standard 31 39 859 867 O
of 40 42 868 870 O
care 43 47 871 875 O
( 48 49 876 877 O
ie 49 51 877 879 O
, 51 52 879 880 O
for 53 56 881 884 O
confirmation 57 69 885 897 O
of 70 72 898 900 O
disease 73 80 901 908 O
progression 81 92 909 920 O
) 92 93 920 921 O

Progression 0 11 922 933 O
following 12 21 934 943 O
both 22 26 944 948 O
standard 27 35 949 957 O
combined 36 44 958 966 B-treatment
modality 45 53 967 975 I-treatment
treatment 54 63 976 985 I-treatment
with 64 68 986 990 I-treatment
radiation 69 78 991 1000 I-treatment
and 79 82 1001 1004 I-treatment
temozolomide 83 95 1005 1017 I-treatment
chemotherapy 96 108 1018 1030 I-treatment
, 108 109 1030 1031 O
as 110 112 1032 1034 O
well 113 117 1035 1039 O
as 118 120 1040 1042 O
anti 121 125 1043 1047 B-treatment
- 125 126 1047 1048 I-treatment
angiogenic 126 136 1048 1058 I-treatment
therapy 137 144 1059 1066 I-treatment
( 145 146 1067 1068 O
ie 146 148 1068 1070 O
, 148 149 1070 1071 O
bevacizumab 150 161 1072 1083 B-treatment
; 161 162 1083 1084 O
patients 163 171 1085 1093 O
not 172 175 1094 1097 O
eligible 176 184 1098 1106 O
for 185 188 1107 1110 O
or 189 191 1111 1113 O
refusing 192 200 1114 1122 O
antiangiogenic 201 215 1123 1137 B-treatment
therapy 216 223 1138 1145 I-treatment
will 224 228 1146 1150 O
also 229 233 1151 1155 O
be 234 236 1156 1158 O
allowed 237 244 1159 1166 O
) 244 245 1166 1167 O

Recovered 0 9 1168 1177 O
from 10 14 1178 1182 O
toxicities 15 25 1183 1193 O
of 26 28 1194 1196 O
prior 29 34 1197 1202 B-treatment
therapy 35 42 1203 1210 I-treatment
to 43 45 1211 1213 O
grade 46 51 1214 1219 B-lower_bound
0 52 53 1220 1221 I-lower_bound
or 54 56 1222 1224 O
1 57 58 1225 1226 B-upper_bound

The 0 3 1227 1230 O
subject 4 11 1231 1238 O
has 12 15 1239 1242 O
evidence 16 24 1243 1251 O
of 25 27 1252 1254 O
acute 28 33 1255 1260 B-chronic_disease
intracranial 34 46 1261 1273 I-chronic_disease
or 47 49 1274 1276 O
intratumoral 50 62 1277 1289 B-chronic_disease
hemorrhage 63 73 1290 1300 I-chronic_disease
either 74 80 1301 1307 O
by 81 83 1308 1310 O
MRI 84 87 1311 1314 B-treatment
or 88 90 1315 1317 O
computerized 91 103 1318 1330 B-treatment
tomography 104 114 1331 1341 I-treatment
( 115 116 1342 1343 I-treatment
CT 116 118 1343 1345 I-treatment
) 118 119 1345 1346 I-treatment
scan 120 124 1347 1351 I-treatment

The 0 3 1352 1355 O
subject 4 11 1356 1363 O
has 12 15 1364 1367 O
inherited 16 25 1368 1377 O
bleeding 26 34 1378 1386 B-chronic_disease
diathesis 35 44 1387 1396 I-chronic_disease
or 45 47 1397 1399 O
coagulopathy 48 60 1400 1412 B-chronic_disease
with 61 65 1413 1417 I-chronic_disease
the 66 69 1418 1421 I-chronic_disease
risk 70 74 1422 1426 I-chronic_disease
of 75 77 1427 1429 I-chronic_disease
bleeding 78 86 1430 1438 I-chronic_disease

The 0 3 1439 1442 O
subject 4 11 1443 1450 O
has 12 15 1451 1454 O
not 16 19 1455 1458 O
recovered 20 29 1459 1468 O
to 30 32 1469 1471 O
National 33 41 1472 1480 O
Cancer 42 48 1481 1487 O
Institute 49 58 1488 1497 O
( 59 60 1498 1499 O
NCI 60 63 1499 1502 O
) 63 64 1502 1503 O
Common 65 71 1504 1510 B-clinical_variable
Terminology 72 83 1511 1522 I-clinical_variable
Criteria 84 92 1523 1531 I-clinical_variable
for 93 96 1532 1535 I-clinical_variable
Adverse 97 104 1536 1543 I-clinical_variable
Events 105 111 1544 1550 I-clinical_variable
( 112 113 1551 1552 I-clinical_variable
CTCAE 113 118 1552 1557 I-clinical_variable
) 118 119 1557 1558 I-clinical_variable
v4.0 120 124 1559 1563 I-clinical_variable
Grade 125 130 1564 1569 I-clinical_variable
â‰¤ 131 132 1570 1571 O
1 133 134 1572 1573 B-upper_bound
from 135 139 1574 1578 O
AEs 140 143 1579 1582 O
( 144 145 1583 1584 O
except 145 151 1584 1590 O
alopecia 152 160 1591 1599 B-chronic_disease
, 160 161 1599 1600 O
anemia 162 168 1601 1607 B-chronic_disease
and 169 172 1608 1611 O
lymphopenia 173 184 1612 1623 B-chronic_disease
) 184 185 1623 1624 O
due 186 189 1625 1628 O
to 190 192 1629 1631 O
surgery 193 200 1632 1639 B-treatment
, 200 201 1639 1640 O
antineoplastic 202 216 1641 1655 B-treatment
agents 217 223 1656 1662 I-treatment
, 223 224 1662 1663 O
investigational 225 240 1664 1679 B-treatment
drugs 241 246 1680 1685 I-treatment
, 246 247 1685 1686 O
or 248 250 1687 1689 O
other 251 256 1690 1695 O
medications 257 268 1696 1707 B-treatment
that 269 273 1708 1712 O
were 274 278 1713 1717 O
administered 279 291 1718 1730 O
prior 292 297 1731 1736 O
to 298 300 1737 1739 O
study 301 306 1740 1745 B-treatment
drug 307 311 1746 1750 I-treatment

The 0 3 1751 1754 O
subject 4 11 1755 1762 O
is 12 14 1763 1765 O
pregnant 15 23 1766 1774 B-pregnancy

The 0 3 1775 1778 O
subject 4 11 1779 1786 O
is 12 14 1787 1789 O
unable 15 21 1790 1796 O
to 22 24 1797 1799 O
undergo 25 32 1800 1807 O
MRI 33 36 1808 1811 B-treatment
scan 37 41 1812 1816 O
( 42 43 1817 1818 O
eg 43 45 1818 1820 O
, 45 46 1820 1821 O
has 47 50 1822 1825 O
pacemaker 51 60 1826 1835 B-treatment
) 60 61 1835 1836 O

